Quality of life in patients with polyneuropathy associated with different types of monoclonal gammopathy of undetermined significance

• Published in: Acta neurologica Belgica 2020-10, Vol.120 (5), p.1133-1138
• Main Authors: Opalic, Milica, Peric, Stojan, Palibrk, Aleksa, Bozovic, Ivo, Bjelica, Bogdan, Stevic, Zorica, Basta, Ivana
• Format: Article
• Language: English
• Subjects: Biomedical and Life Sciences; Biomedicine; Medicine/Public Health; Neurology; Neuroradiology; Neurosciences; Original Article
• ISSN: 0300-9009; 2240-2993
• DOI: 10.1007/s13760-019-01155-x

Polyneuropathy associated with monoclonal gammopathy of undetermined significance (MGUS-PNP) has a chronic and slowly progressive course but can lead to significant disability and reduced quality of life (QoL). The aim of this study was to analyze QoL in MGUS-PNP patients and to determine its predictors. Our study included 51 patients diagnosed with MGUS-PNP (23.5% with IgM, 66.7% IgG or IgA, 7.8% undetermined paraprotein, 2.0% light chains). QoL was assessed using the SF-36 questionnaire. The Medical Research Council Sum Score (MRC-SS), INCAT disability and sensory scores, ataxia score, Krupp’s Fatigue Severity Scale and Beck’s Depression Inventory were also used. Total SF-36 score was 50.0 ± 21.4 and no difference was observed between IgM and IgG/IgA MGUS-PNP. Physical composite score was worse than mental (44.4 ± 21.4 vs. 54.5 ± 20.9). Following factors showed correlation with SF-36 total score in univariate analysis: INCAT disability score, MRC-SS, INCAT sensory score, level of ataxia, fatigue and depression ( p